This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

Biotech Stock Mailbag: Fibrocell Science

BOSTON ( TheStreet) -- Thanks to everyone who joined me in the first Biotech Stock Mailbag Live Chat last Friday. I enjoyed, it and the feedback from many of you was so positive that I've decided to make the Mailbag Live Chat a monthly event.

The next live chat will take place Friday, June 17 at 11 a.m. ET. I hope you'll be able to participate.

Keith M. writes, "I was wondering whether you have heard of a company called Fibrocell Science (FCSC) and could extend me an opinion on it. They make a product to treat wrinkles and have a PDUFA date of June 22. Thanks in advance for any input you may have."

Forget about stem cell research to find cures for serious and life-threatening diseases. What mankind really demands is a stem-cell therapy to smooth out the unsightly smile lines on the rich and pampered faces of the denizens of Manhattan's Upper East Side.

All snark aside, Fibrocell is seeking U.S. Food and Drug Administration approval for laViv, a personalized cell therapy for the treatment (smoothing out) of nasolabial fold wrinkles -- those are the skin folds that run from each side of the nose to the corners of the mouth.

What makes laViv different from Botox and the myriad of dermal fillers used commonly in cosmetic skin procedures today is its active ingredient -- a patient's own fibroblasts. These are a form of stem cell that matures into connective tissue fibers and help give skin strength and elasticity.

Fibrocell makes laViv by first removing a small tissue sample from behind a patient's ear. The tissue sample is then sent to Fibrocell's manufacturing facility, where fibroblasts are isolated and grown in a lab to form a personalized cellular therapy. Once prepared and shipped back to the doctor, the fibroblast-containing cell therapy, now known as laViv, is reinjected into the patient's face to fill in and smooth out wrinkle lines.

I'm a guy, and a low-maintenance one at that, so going through all this trouble to harvest and grow stem cells for a vain, aesthetic procedure seems utterly ridiculous. But heck, we know that billions of dollars are spent on cosmetic surgery in this country, so perhaps Fibrocell has a shot. The imprimatur of an FDA approval could prove helpful to the company as well, especially against the all the modern-day witch doctors out there peddling pseudo-scientific stem-cell snake oil to wrinkled women. (Google "stem cell facelifts" and you'll see what I mean.)

1 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
DSCI $7.74 0.52%
EXEL $3.12 2.30%
MNKD $5.74 -3.40%
AAPL $126.24 -1.80%
FB $81.21 0.39%

Markets

DOW 18,133.05 +36.15 0.20%
S&P 500 2,101.35 +2.82 0.13%
NASDAQ 4,982.8550 +15.7140 0.32%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs